CONTACT | Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

NextGen Healthcare Commemorates 2020 National Health Center WeekOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)---- $NXGN #AmbulatoryHealthcare--In Support of NHCW, NextGen Healthcare Donated Supplies to 30 U.S. CHCs Recognized for Patient Advocacy and Civic Action During COVID-19

 

BioSpyder Files Action Against HTG Molecular Diagnostics in Federal CourtOpen in a New Window

CARLSBAD, Calif.--(BUSINESS WIRE)--On Wednesday, August 12, 2020, BioSpyder Technologies, Inc. (“BioSpyder”) filed a civil action in the federal court for the Northern District of California, seeking a declaratory judgment that the BioSpyder TempO-Seq gene expression profiling assay does not infringe any valid claim in U.S. Patent No. 8,741,564 (“the ’564 patent”) for Quantitative Nuclease Protection Assay (QNPA) and Sequencing (QNPS) Improvements. HTG Molecular Diagnostics, Inc. (“HTG”) has re

 

Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial ResultsOpen in a New Window

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2020. “The past four months have been truly momentous for the company. The successful second interim look showed how valuable our diagnostic agent will be for the effective manag

 

Schwazze Announces Second Quarter 2020 Financial Results and Provides Company UpdateOpen in a New Window

DENVER--(BUSINESS WIRE)--Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) ("Schwazze " or “the Company"), today announced financial results for its second quarter ended June 30, 2020. Justin Dye, Chairman and Chief Executive Officer of Schwazze shared, “We are building a unique, differentiated business with leading cannabis brands and believe Schwazze is well-positioned to become a leading seed to sale company as our industry consolidates. During the second quarter,

 

Aptinyx Reports Second Quarter 2020 Financial Results and HighlightsOpen in a New Window

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators. “Despite the continuing COVID-19 health emergency, we have made important progress in advancing our pipeline of clinical-stag

 

CONMED Corporation Announces Quarterly Cash DividendOpen in a New Window

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2020 to all shareholders of record as of September 15, 2020. About CONMED Corporation CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedi

 

Urovant Sciences Reports Fiscal First Quarter 2020 ResultsOpen in a New Window

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Reports Fiscal First Quarter 2020 Results

 

Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational HighlightsOpen in a New Window

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights. “We set out in 2016 to become the leading precision oncology company focused on synthetic lethality in genomic instability and DNA da

 

TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business ResultsOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals (NASDAQ:TFFP) reports second quarter 2020 financial and business results - Conference call today at 4:30 PM ET

 

TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamideOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals in worldwide licensing agreement with UNION therapeutics for its Thin Film Freezing technology in combination with niclosamide.

 

Coast Diagnostics Growing to Meet Needs of COVID-19 Rapid TestingOpen in a New Window

MOBILE, Ala.--(BUSINESS WIRE)--While many concerned Gulf Coast residents wait for days to receive results from COVID-19 testing, a newly-expanded local lab is processing up to 4,000 rapid tests per day with results in 24-48 hours. Coast Diagnostics, a full-service reference lab at 4674 Airport Boulevard in Mobile, has grown from a quiet, local lab with four employees to a 7,000 square foot regional cog in the testing process of the battle against COVID-19. CEO Brian Ward says, “Coast is proud t

 

Premier Medical Laboratory Services Named Among Top Genetic Diagnostic Companies of 2020 by Healthcare Tech OutlookOpen in a New Window

GREENVILLE, S.C.--(BUSINESS WIRE)--Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication. The designation, earned by the Greenville, SC laboratory, comes with recognition for their providing the most advanced diagnostic testing solutions with accuracy and efficiency through employing the latest in science and technology. One of the reasons PMLS

 

Company Profile for NMS LabsOpen in a New Window

--(BUSINESS WIRE)--NMS Labs is a leading bioanalytical toxicology and forensic sciences laboratory providing esoteric clinical and forensic services to physicians, attorneys, the criminal justice system, clinical reference labs, pharmaceutical companies, and consumer products manufacturers. As part of our services, NMS Labs’ professionals interpret our laboratory testing results to resolve client-specific issues and provide expert witness testimony and consulting support for both civil and crim

 

NMS Labs Appoints Dan Monahan as President and Chief Executive OfficerOpen in a New Window

HORSHAM, Pa.--(BUSINESS WIRE)--NMS Labs is pleased to announce Dan Monahan has joined the company as President and Chief Executive Officer.

 

Manhattan Scientifics Announces Rising Price & VolumeOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Manhattan Scientifics, Inc. (OTCQB:MHTX) owns 50+ Million shares of its former wholly-owned subsidiary cancer diagnostic company Imagion Biosystems Ltd. (AX:IBX). Volume trading yesterday exceeded 80 million shares @ high of AU $0.010. Manhattan Scientifics acquired and funded 10 years early R&D of IBX now anticipating possible US FDA approval to initiated human cancer testing. About Imagion Biosystems Imagion Biosystems (www.imgionbiosystems.com) is developing a

 

Sleep Number Announces New Sleep Innovations, Deepens Ongoing Commitment to Research Linking Sleep to HealthOpen in a New Window

MINNEAPOLIS--(BUSINESS WIRE)--Today Sleep Number Corporation (Nasdaq: SNBR) announced its latest product innovations and the next steps in its ongoing commitment to demonstrate the direct link between quality sleep and health. The company’s award-winning 360® smart beds - which have been proven to deliver up to 100 hours more restful sleep per year – are at the heart of Sleep Number’s efforts to meaningfully advance the science of sleep1. Enabled by its proprietary SleepIQ® technology, the oper

 

Purdue’s Avrio Health L.P. Reports Preliminary In Vitro Test Results on Study Assessing Betadine Gargle Against COVID-19Open in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)--THIS RELEASE DISCUSSES INVESTIGATIONAL USES OF BETADINE AND IS NOT INTENDED TO CONVEY CONCLUSIONS ABOUT ITS EFFICACY OR SAFETY IN TREATING AND/OR PREVENTING COVID-19 OR ANY OTHER VIRUSES. BETADINE ANTISEPTIC PRODUCTS HAVE NOT BEEN DEMONSTRATED TO BE EFFECTIVE AGAINST SARS-COV-2 OR ANY OTHER VIRUSES IN VIVO, NOR HAVE ANY CLINICAL STUDIES BEEN CONDUCTED TO ASSESS ITS SAFETY OR EFFECTIVENESS AS A VIRUCIDAL AGENT. THERE IS NO GUARANTEE THAT STUDIES EVALUATING THE E

 

CE Marking Received for Core European Product, DyeVert Power XTOpen in a New Window

MINNEAPOLIS & MELBOURNE, Australia--(BUSINESS WIRE)--Osprey Medical, Inc. (ASX:OSP) (Osprey or the Company) is pleased to announce that the Company has received CE Marking for the DyeVert Power XT 2nd generation device. The CE Marking approval for its DyeVert Power XT device means the product can now be marketed and sold across Europe. Europe is a core market for Osprey and a significant player in the global power injector market. Our DyeVert Power XT device is expected to form a core product i

 

 Southeastern Grocers Offers Contactless Prescription Delivery and Expands Commitment to Customer SafetyOpen in a New Window

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Southeastern Grocers offers contactless prescription delivery and expands commitment to customer safety

 

DeltaTrak Enhances Its Cold Chain Restart Program to Help Customers Battle COVID-19Open in a New Window

PLEASANTON, Calif.--(BUSINESS WIRE)-- #backtowork--DeltaTrak enhances its Cold Chain Restart Program with safer and more efficient options for temperature measurement and hand sanitization.

 

PPG Receives DOE Funding for Energy-Saving Automotive Paints and CoatingsOpen in a New Window

PITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today announced a partnership with the U.S. Department of Energy (DOE) Lawrence Berkeley National Laboratory (LBNL) for a research initiative aimed at developing energy-efficient coatings systems for the automotive industry. The PPG project – “Modeling Coating Flow and Dynamics during Drying” – was selected to receive funding through the DOE High Performance Computing for Energy Innovation (HPC4EI) program. PPG scientists will collaborate with LBNL ex

 

WGU Receives Grant to Support Underserved Students Impacted by COVID-19Open in a New Window

SALT LAKE CITY--(BUSINESS WIRE)--Western Governors University (WGU) and WGU Advancement—the university’s fundraising arm—announced today that the university will be able to implement four projects that remove barriers to quality, access, and outcomes across the education-to-opportunity lifecycle that have been a result of the COVID-19 pandemic with support from the Bill & Melinda Gates Foundation. Given COVID-19’s impact on higher education—from permanent campus closures to decreased public

 

Bioceres Crop Solutions Subsidiary Rizobacter Argentina S.A. Completes $17.0 Million Offering of Series IV Corporate BondsOpen in a New Window

ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (“Bioceres” or the “Company”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced today that its subsidiary Rizobacter Argentina S.A. (“Rizobacter”) has completed a $17.0 million public offering of Series IV corporate bonds under its global program of corporate bonds in the Argentine market. The bonds mature in Aug

 

Global Immune Health Supplements Market to surpass US$ 22,702.4 million by 2027, Says Coherent Market Insights (CMI)Open in a New Window

SEATTLE--(BUSINESS WIRE)-- #ImmuneHealthSupplements--North America is expected to be the most lucrative region in the immune health supplements market due to the launch of new products.

 

Inc. Magazine Recognizes The Inception Company as One of America’s Fastest-growing Private CompaniesOpen in a New Window

FAIRFIELD, N.J.--(BUSINESS WIRE)--The Inception Company, a technology-driven production company that builds and supports virtual engagement platforms and services, announced today that it has been recognized for the first time on the Inc. 5000 list, the most highly esteemed ranking of the nation’s fastest-growing private companies. Companies are chosen for the list based on their growth from 2016-2019. This year’s Inc. 5000 have shown unprecedented growth compared with prior years and have gene

 

HARMAN Launches AccuAlertMe – An Enterprise Platform to Enable Workplace Safety for Employees and VisitorsOpen in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)-- #Harman--HARMAN, a wholly-owned subsidiary of Samsung Electronics Co. Ltd., focused on connected technologies for automotive, consumer and enterprise markets, today announced the launch of AccuAlertMe, a unique solution to help companies, employees and visitors navigate the risks of COVID-19 while re-opening facilities of business. Built by HARMAN’s Digital Transformation Solutions (DTS) business unit, with a central focus on employee safety, the platform offers a secur

 

Medidata Announces Launch of Medidata Detect, its Centralized Statistical Monitoring Solution for Clinical TrialsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices. Medidata Detect, part of Medidata’s industry-leading, regulatory-compliant and unified Medidata Rave Clinical Cloud platform, helps customers manage data quality, monitor site performance and promote patient safety by uncov

 

Happify Health Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health StartupsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--CB Insights today named digital therapeutics leader, Happify Health, to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. Happify Health has been recognized for their achievements in the ranking’s Disease Management and Therapeutics category. The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories

 

CSG and Clean Republic Form Strategic Alliance to Offer Market-Leading Pathogen Protection Products and ServicesOpen in a New Window

CHICAGO--(BUSINESS WIRE)-- #csg--CSG and Clean Republic Form Strategic Alliance to Offer Market-Leading Pathogen Protection Products and Services

 

Sema4 Named to the 2020 CB Insights Digital Health 150, a List of the Most Innovative Digital Health StartupsOpen in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)-- #BigData--Sema4 recognized for its cutting-edge precision medicine solutions that enable providers and patients to dramatically improve health outcomes.

 

Global Osteogenesis Imperfecta Treatment Market to Surpass US$ 780.4 Million by 2027, Says Coherent Market Insights (CMI)Open in a New Window

SEATTLE--(BUSINESS WIRE)-- #OsteogenesisImperfectaTreatment--Europe is expected to be the most lucrative region in the global osteogenesis imperfecta treatment market by 2027.

 

HB NEXT and Passpoint Security Announce COVID-19 Safety PartnershipOpen in a New Window

LAWRENCEVILLE, Ga.--(BUSINESS WIRE)-- #covid19--HB NEXT and Passpoint Security announce a partnership to provide Clear2, an innovative COVID-19 screening solution that can be used in any industry.

 

Mercer and HLTH Announce Second Annual Employer Program at HLTH VRTL 2020Open in a New Window

NEW YORK--(BUSINESS WIRE)--Mercer, a global leader in redefining the world of work, reshaping retirement and investment outcomes, and unlocking real health and well-being, and a business of Marsh & McLennan (NYSE: MMC), and HLTH, the leading platform bringing together the entire health ecosystem, announced today the second annual “Employer Program” taking place at HLTH VRTL 2020. Based on the success of the inaugural Employer Program at HLTH 2019, attendees this year will have the ability t

 

Madison Core Laboratories Initiates New Innovation Effort to Better Serve ClientsOpen in a New Window

HUNTSVILLE, Ala.--(BUSINESS WIRE)-- #coronavirus--Madison Core Laboratories innovates and expands COVID-19 (SARS-CoV-2) testing with Entopsis Coronavirus technology.

 

Experity Announces Record Urgent Care Patient Volumes in July Amid PandemicOpen in a New Window

MACHESNEY PARK, Ill.--(BUSINESS WIRE)--Experity, the leading provider of clinical and practice management software in the urgent care space, today published a report showing more patient visits in July than any other month this year, according to its client base of more than 5,700 clinics. Additionally, on Monday, July 6 urgent care clinics recorded over 105,000 patient visits, marking the highest single-day visit volume number of 2020. Experity is partnering with Urgent Care Association (UCA)

 

RapidAI Receives FDA Clearance of Rapid LVO For Identification of Suspected Large Vessel OcclusionsOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)-- #FDA--RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions). Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sen

 

Hyperfine Research Receives 510(k) Clearance from US FDA for Market-Ready Swoop™ Portable MRI SystemOpen in a New Window

GUILFORD, Conn.--(BUSINESS WIRE)-- #MedTech--Hyperfine has received 510(k) clearance from the US FDA for its category-defining portable MRI technology, the Swoop™ Portable MR imaging system.

 

Robotic Assistance Devices Receives Multi Unit Order for Face Mask Detection Enabled ROSAsOpen in a New Window

HENDERSON, Nev.--(BUSINESS WIRE)---- $AITX #robot--Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced that its wholly owned subsidiary Robotic Assistance Devices (RAD) has received an order for three ROSA units to be deployed in the greater Los Angeles area. The order is a direct result of the highly visible face mask enforcement controversy and increasing press coverage of RAD’s innovative solution. NBC-owned KNBC-TV aired a lengthy segment during their August 11, 2020 11 pm broa

 

FDA Approves Gadavist® (gadobutrol) Imaging Bulk PackageOpen in a New Window

INDIANOLA, Pa.--(BUSINESS WIRE)--The FDA announced the approval of the Gadavist® (gadobutrol) Imaging Bulk Package. The Gadavist® (gadobutrol) Imaging Bulk Package will be available in two presentation sizes, 30 mL and 65 mL, and allows for weight-based dosing with a 24-hour stand time for multi-patient dosing. In conjunction with the bulk package approval, the FDA also cleared the MEDRAD® Imaging Bulk Package Transfer Spike that is indicated for the transfer of Gadavist® contrast media as supp

 

Phreesia Partners with AdventHealth to Provide Zero-Contact Intake Across its Hospital and Ambulatory Care SettingsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Phreesia, the nation’s leading patient intake platform, is proud to announce it has partnered with AdventHealth, one of the nation’s largest faith-based healthcare systems, to provide patients with a safe, contactless intake experience across more than 1,000 AdventHealth hospitals, physician practices and urgent care centers. “Using Phreesia has helped us scale an intake workflow that reduces exposure between patients and staff during in-person visits,” said Jessica B

 

Model N Continues to Lead in Life Sciences MarketOpen in a New Window

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, announced today that it continues to achieve significant momentum within Life Sciences. Model N’s ongoing progress this year is illustrated by a number of factors including the addition of new customers and notable customer/product expansion within the mid-market segment. Model N has also achieved numerous customer go-live milestones and transitioned multiple customers to its Softwa

 

United Health Foundation Donates $1,250,000 to ECU to Support Maternal Health Needs of North Carolina Amid COVID-19 PandemicOpen in a New Window

GREENVILLE, N.C.--(BUSINESS WIRE)--The United Health Foundation has donated $1,250,000 to East Carolina University’s Brody School of Medicine to expand access to health care and improve health outcomes for North Carolina’s mothers and babies. The funding will expand telepsychiatry services to better address the mental health needs of expectant and new mothers, develop and deploy a new obstetric care model for high-risk patients, and address food insecurity among pregnant women. This effort is p

 

E25Bio Receives a Pair of Grant Awards to Expand Coronavirus and Arbovirus TestingOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Covid19--E25Bio, rapid diagnostic innovators, announces award funding of $4.14M from the Bill & Melinda Gates Foundation and $1.68M from the NIH’s Small Business Innovation Research (SBIR) program. The pair of funding awards comes months after the startup announces funding from Khosla Ventures to develop and commercialize a rapid, inexpensive diagnostic for the COVID-19 pandemic. Launched in 2000, the Gates Foundation focuses on improving global health and reducing

 

Barclays Launches Systematic Study of ESG-Focussed US Equity FundsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--ESG-focussed mutual funds are attracting large inflows, but fundamental challenges remain in defining what constitutes an ESG-labelled equity fund. In a systematic study of US equity funds, Barclays’ Quantitative Portfolio Strategy (“QPS”) team finds that ESG-labelled funds do not necessarily provide more ESG exposure than conventional funds. “Responsible investing has become a hot topic in financial markets in recent years with many investors racing to integrate Envi

 

Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 PneumoniaOpen in a New Window

ENGLEWOOD, N.J.--(BUSINESS WIRE)--Enzychem Lifesciences Announces FDA Acceptance of Phase 2 Study of EC-18 in Preventing Acute Respiratory Distress Syndrome (ARDS) due to COVID-19

 

Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call SeriesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company, today announced that the company’s management team will present a corporate overview as part of Oppenheimer’s Private Life Sciences Company Call Series on Wednesday, August 19, 2020 at 2:15 p.m. ET. Sekar Kathiresan, M.D., co-founder and chief executive officer; Andrew Bellinger, M.D., Ph.D., chief scientific officer; and Kiran Musunuru, M.D., Ph.D., MPH, co-founder and senior scientific advisor, wi

 

CytRx’s Board of Directors Sends Important Letter to Stockholders to Expose Dissident Investor and his Misguided CampaignOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has mailed a letter to stockholders in connection with the Company’s Annual Meeting of Stockholders that is scheduled for September 3, 2020. Below please find the full text of the letter sent to CytRx stockholders. *** August 13, 2020 Dear Stockholders, We want to alert you to

 

Certara Announces First Enrollee in International Registry to Assess Preventative Therapies in Healthcare Workers Exposed to COVID-19Open in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)--Certara's registry of healthcare workers will collect information on risk factors for developing COVID-19 and the use of preventative therapies.

 

AstraZeneca Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu SeasonOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the first shipment of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal) doses in the US for the 2020-2021 influenza season. FLUMIST QUADRIVALENT, the only nasal-spray flu vaccine, is indicated for those ages 2 through 49. It may not prevent influenza in everyone who gets vaccinated. The Centers for Disease Control and Prevention (CDC) has recently issued statements encouraging the importance of flu vaccination rates for the

 

Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular AtrophyOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces that SRK-015 has received Rare Pediatric Disease Designation from U.S. FDA for the treatment of Spinal Muscular Atrophy

 

Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateOpen in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.

 

scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business UpdateOpen in a New Window

BURLINGTON, Mass.--(BUSINESS WIRE)--scPharmaceuticals reports financial results for the 2nd quarter and provided a business update including preparations for 12.30.20 FUROSCIX PDUFA date

 

BELLUS Health Reports Second Quarter 2020 Financial Results and Business HighlightsOpen in a New Window

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2020. PROGRAM AND CORPORATE HIGHLIGHTS Announced topline results from the Phase 2 RELIEF clinical trial of BLU-5937 in patients with refractory c

 

4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry DiseaseOpen in a New Window

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to 4D-310 for Fabry disease, a debilitating lysosomal storage disorder caused by a deficiency of alpha-galactosidase A (AGA) enzyme activity. 4D-310 is a gene medicine engineered with a proprietary optimized AAV capsid disc

 

TransEnterix Announces Appointment of Shameze Rampertab as Chief Financial OfficerOpen in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Shameze Rampertab has been appointed as the Company’s Executive Vice President and Chief Financial Officer, effective August 24, 2020. “We are delighted to welcome Shameze to our team during this important time in TransEnterix’s journey,” said Anthony Fern

 

BiomX Reports Second Quarter 2020 Financial Results and Provides Business UpdateOpen in a New Window

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2020. “Following proof of concept clinical results for our phage therapy cocktail BX001 in acne-prone skin earlier this year, we continue to advance the development of multiple phage therapy candidates that have the po

 

Karuna Therapeutics Appoints Laurie Olson to Board of DirectorsOpen in a New Window

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, today announced the appointment of Laurie Olson to its Board of Directors effective August 12, 2020. Ms. Olson will be part of the nominating and corporate governance committee. “We are pleased to welcome Laurie to our b

 

Avellino Hits the 1-Million Genetic Test MilestoneOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)-- #avagen--Avellino announces milestone of performing over 1-million of their genetic and molecular diagnostic tests, including more than 180,000 COVID-19 tests.

 

Applied StemCell Awarded ~USD 2 mil NIH grant for Advancing its TARGATT Technology for Therapeutic Gene EditingOpen in a New Window

MILPITAS, Calif.--(BUSINESS WIRE)-- #AntibodyDiscovery--Applied StemCell Awarded ~USD 2 mil NIH grant for Advancing its TARGATT™ Technology for Therapeutic Gene Editing

 

Seoul Viosys to Develop a Cancer Diagnosis Technology for Companion Animals with Violeds TechnologyOpen in a New Window

ANSAN, South Korea--(BUSINESS WIRE)-- #CancerDiagnosisTechnology--Seoul Viosys developed an advanced concept technology for early diagnosis of cancer in companion animals with its ultraviolet LED Violeds technology

 

Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular DegenerationOpen in a New Window

LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope announces initiation of Phase II programme evaluating its investigational gene therapy, GT005, for dry age-related macular degeneration.

 

FDA Accepts Application for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All IndicationsOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair® (omalizumab) across all approved U.S. indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregive

 

Schrödinger Announces Pricing of Public OfferingOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the pricing of an underwritten public offering.

 

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common StockOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock.

 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 6,700 establishments and research organizations in the BioPharma, MedTech, HealthIT & BioAg that collectively employ nearly 94,000 Floridians.